⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

Most bladder cancer is caught early — and that is good news. About 75% of bladder cancers are non-muscle-invasive at diagnosis, meaning the tumor has not grown into the deep muscle wall. These are highly treatable and often manageable for years, though they require ongoing surveillance because recurrence is common.
Staging determines everything. The single most important question is whether the cancer has invaded the bladder muscle. Non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) bladder cancer are treated completely differently. Make sure you understand your stage.
BCG is the cornerstone treatment for high-risk NMIBC. Bacillus Calmette-Guérin (BCG) is a live tuberculosis vaccine instilled directly into the bladder. It stimulates the immune system to attack cancer cells. BCG remains the most effective treatment for preventing recurrence and progression of high-risk non-muscle-invasive bladder cancer.
If BCG fails, there are now real options. For decades, patients whose cancer did not respond to BCG had few choices beyond bladder removal. Now, nadofaragene firadenovec (Adstiladrin, the first gene therapy for bladder cancer), pembrolizumab, and other agents offer bladder-sparing alternatives.
For muscle-invasive disease, cisplatin-based chemotherapy before surgery saves lives. Neoadjuvant chemotherapy (given before radical cystectomy) improves overall survival by approximately 5–8%. If you are fit enough for cisplatin, this should be part of your plan.
Enfortumab vedotin + pembrolizumab has transformed advanced bladder cancer. The EV-302/KEYNOTE-A39 trial showed this combination nearly doubled overall survival compared to chemotherapy in first-line metastatic disease. This is the biggest breakthrough in bladder cancer treatment in decades.
FGFR testing matters. About 15–20% of advanced bladder cancers have FGFR alterations. Erdafitinib (Balversa) targets these specifically. Ask your team whether your tumor has been tested for FGFR mutations.
Get to a high-volume center for complex decisions. Radical cystectomy, trimodality therapy, and clinical trial access all benefit from centers that manage many bladder cancer patients. A second opinion at a high-volume center is strongly recommended for muscle-invasive or BCG-unresponsive disease.

▼ Collapse

Understanding Bladder Cancer

Bladder cancer begins in the cells lining the inside of the bladder — the organ that stores urine. The most common type, urothelial carcinoma (also called transitional cell carcinoma), accounts for about 90% of all bladder cancers. Less common types include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma, each with different treatment approaches.

Bladder cancer is the fourth most common cancer in men in the United States. It is about three to four times more common in men than women, though women tend to be diagnosed at more advanced stages and may have worse outcomes stage-for-stage.

Approximately 83,000 new cases per year in the United States
Approximately 17,000 deaths per year in the United States
Median age at diagnosis is about 73 years
Lifetime risk is approximately 1 in 27 for men and 1 in 89 for women
About 75% are non-muscle-invasive at diagnosis (stages Ta, T1, CIS)
Smoking is the single greatest risk factor, responsible for roughly half of all cases
Occupational exposure to aromatic amines (dyes, rubber, leather, paint) is the second most important risk factor

Urothelial carcinoma (transitional cell): About 90% of cases. Arises from the urothelium, the specialized lining of the bladder. This is the type discussed throughout most of this guide.
Squamous cell carcinoma: About 3–5% in Western countries. More common in regions where schistosomiasis (a parasitic infection) is endemic. Often diagnosed at advanced stages.
Adenocarcinoma: About 1–2%. May arise from the urachus (a structure connecting the bladder to the umbilicus during fetal development).
Small cell / neuroendocrine carcinoma: Rare but aggressive. Treated more like small cell lung cancer (with cisplatin/etoposide) than typical bladder cancer.
Variant histologies: Micropapillary, plasmacytoid, sarcomatoid, and nested variants are important to identify because they tend to behave more aggressively and may require more aggressive treatment approaches.

The most important concept in this guide: Bladder cancer treatment in 2026 is determined by two critical factors: (1) whether the cancer has invaded the muscle wall of the bladder, and (2) your molecular profile. The treatment landscape has changed dramatically with the approval of enfortumab vedotin, pembrolizumab, erdafitinib, and nadofaragene firadenovec. Ask your team about all available options.

Newly Approved in 2026: Two important new options were approved by the FDA in May 2026.

FDA-APPROVED Durvalumab (Imfinzi) added to BCG — for adults with high-risk non-muscle-invasive bladder cancer (NMIBC) who have not yet been treated with BCG (“BCG-naive”). Durvalumab is an immunotherapy that helps the immune system fight cancer; this is the first PD-L1 immunotherapy approved to be combined with BCG for BCG-naive high-risk NMIBC. It was studied in the POTOMAC trial (NCT03528694).
FDA-APPROVED Atezolizumab (Tecentriq) after bladder-removal surgery — for adults with muscle-invasive bladder cancer (MIBC) who, after having their bladder removed (cystectomy), still have tiny traces of tumor DNA detectable in the blood (“ctDNA molecular-residual-disease positive”) on an FDA-authorized test. This is the first approval in bladder cancer that uses a blood test for circulating tumor DNA to guide which patients receive immunotherapy after surgery. It was studied in the IMvigor011 trial (NCT04660344).

Key Breakthroughs in Bladder Cancer

The bladder cancer treatment landscape has changed more in the past five years than in the preceding three decades. Here are the most important advances:

FDA-APPROVED The EV-302/KEYNOTE-A39 trial established enfortumab vedotin (an antibody-drug conjugate targeting Nectin-4) combined with pembrolizumab (a PD-1 checkpoint inhibitor) as the new first-line standard for locally advanced or metastatic urothelial carcinoma. This combination nearly doubled median overall survival compared to gemcitabine-cisplatin or gemcitabine-carboplatin chemotherapy (31.5 months vs. 16.1 months). This is the most significant advance in bladder cancer treatment history.

FDA-APPROVED Nadofaragene firadenovec (Adstiladrin), approved by the FDA in December 2022, is the first gene therapy approved for any non-blood cancer. It is an adenovirus-based vector that delivers the interferon alfa-2b gene directly into bladder cells, causing them to produce interferon locally to fight cancer. It is approved for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ (CIS). In clinical trials, about 53% of patients with CIS achieved a complete response at 3 months.

FDA-APPROVED Erdafitinib is a targeted therapy for patients with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 or FGFR2 genetic alterations. The THOR trial (NCT03390504) showed erdafitinib improved overall survival compared to chemotherapy in previously treated patients with FGFR-altered tumors. About 15–20% of advanced bladder cancers have these alterations.

FDA-APPROVED The JAVELIN Bladder 100 trial showed that switching to avelumab (a PD-L1 checkpoint inhibitor) as maintenance therapy after responding to or having stable disease on first-line platinum-based chemotherapy improved overall survival compared to best supportive care alone (21.4 months vs. 14.3 months). This established a new standard: patients who do not progress on first-line chemo should receive avelumab maintenance.

FDA-APPROVED The CheckMate-274 trial showed that nivolumab given after radical cystectomy for high-risk muscle-invasive bladder cancer (especially in patients who did not receive neoadjuvant cisplatin) roughly doubled disease-free survival compared to placebo. This provides a new option for patients at high risk of recurrence after bladder removal.

FDA-APPROVED TAR-200 (brand name Inlexzo) is an intravesical drug delivery system that slowly releases the chemotherapy drug gemcitabine directly into the bladder over several weeks via a small, pretzel-shaped device placed during a routine office cystoscopy. The FDA approved Inlexzo for adults with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors — a group with few prior bladder-sparing options. In the SunRISe trials it produced high complete-response rates, offering an alternative to radical cystectomy for some patients. Discuss eligibility and monitoring with your urologist.

Note: A separate investigational device, TAR-210, releases erdafitinib (an FGFR inhibitor) into the bladder and is being studied for FGFR-altered bladder cancer in clinical trials — it is not the same product as TAR-200/Inlexzo.

Diagnosis: The Tests You Need

Bladder cancer is usually first suspected when blood appears in the urine (hematuria). A thorough diagnostic workup determines the type, grade, and stage of the cancer — all of which drive the treatment plan.

Cystoscopy involves inserting a thin, flexible camera (cystoscope) through the urethra into the bladder to directly visualize the bladder lining. This is the primary diagnostic tool for bladder cancer. It can be done in a urologist’s office under local anesthesia. Blue-light cystoscopy (photodynamic diagnosis) uses a special light-sensitive drug and blue light to detect flat lesions like carcinoma in situ (CIS) that may be missed under standard white light.

TURBT is both diagnostic and therapeutic. Under anesthesia, the urologist uses a specialized instrument to remove (resect) the visible tumor from the bladder wall. The tissue is sent to pathology to determine the tumor type, grade (low or high), and critically, the depth of invasion — whether it reaches the muscularis propria (the deep muscle layer). A re-staging TURBT is often performed 2–6 weeks after the initial TURBT for high-grade T1 tumors to ensure accurate staging and complete resection. This second look is critical because up to 40% of initial T1 tumors are upstaged or found to have residual disease.

Urine cytology: Urine is examined under a microscope for cancer cells. Best at detecting high-grade tumors and CIS; less sensitive for low-grade tumors.
Urine biomarker tests: FDA-approved tests (e.g., UroVysion FISH, Cxbladder, BladderChek) can supplement cytology. No single urine test replaces cystoscopy.
CT urogram: A CT scan with contrast that images the kidneys, ureters, and bladder (the entire urinary tract). Important for detecting upper tract tumors, which occur in 2–5% of bladder cancer patients.
MRI of the pelvis: Increasingly used for local staging of muscle-invasive disease. The VI-RADS scoring system helps predict muscle invasion before surgery.
PET/CT: Used for staging metastatic disease. Less useful for local bladder staging.

Staging — The Most Important Information

Bladder cancer staging describes how deeply the tumor has grown into the bladder wall and whether it has spread. The stage drives the entire treatment plan.

Stage	Description	Treatment Approach
Ta (Low Grade)	Papillary tumor confined to the inner lining (urothelium); does not invade the lamina propria	TURBT + surveillance. Intravesical chemotherapy (gemcitabine or mitomycin) for recurrence reduction.
Ta (High Grade) / T1	High-grade papillary tumor (Ta HG) or tumor invading the lamina propria (T1) but not the muscle	TURBT + re-staging TURBT + BCG induction and maintenance. Close surveillance.
CIS (Tis)	Carcinoma in situ — flat, high-grade cancer confined to the urothelium. No visible mass but aggressive biology.	BCG induction + maintenance. Close surveillance with cystoscopy and cytology.
T2	Tumor invades the muscularis propria (deep muscle of the bladder wall)	Neoadjuvant cisplatin-based chemotherapy + radical cystectomy, OR trimodality therapy (TMT).
T3–T4	Tumor extends beyond the bladder wall (T3) or invades adjacent organs (T4)	Neoadjuvant chemotherapy + radical cystectomy. Radiation options in select cases. Systemic therapy.
N+ / M+	Spread to lymph nodes (N+) or distant organs (M+ — metastatic: lung, bone, liver)	Systemic therapy: enfortumab vedotin + pembrolizumab (preferred) or platinum-based chemotherapy.

Key question for your urologist: “Does my pathology report show muscularis propria (detrusor muscle) in the specimen? If not, is a re-staging TURBT needed?” Without muscle in the specimen, the pathologist cannot determine whether the cancer has invaded the muscle, and staging is incomplete.

What is the grade and stage of my bladder cancer?
Was muscularis propria (muscle) present in my TURBT specimen?
Do I need a re-staging TURBT?
Is there carcinoma in situ (CIS) in addition to the main tumor?
Have you checked for upper tract disease with a CT urogram?
Are there any variant histology features (micropapillary, plasmacytoid, etc.)?
Should my tumor be tested for FGFR alterations or PD-L1 expression?
Based on my stage, what are my treatment options?

Non-Muscle-Invasive Bladder Cancer (NMIBC)

NMIBC accounts for about 75% of bladder cancers at diagnosis. It includes stages Ta, T1, and CIS (Tis). The primary treatment is TURBT followed by intravesical therapy. The challenge with NMIBC is its high recurrence rate — up to 50–70% of patients will experience recurrence, and 10–20% will progress to muscle-invasive disease.

Low risk: Small, solitary, low-grade Ta tumors. Managed with TURBT alone plus surveillance. Single immediate post-TURBT intravesical gemcitabine or mitomycin C reduces recurrence by about 35%.
Intermediate risk: Recurrent low-grade Ta, multiple low-grade Ta tumors, or large (>3 cm) low-grade Ta. Treated with TURBT + intravesical chemotherapy (gemcitabine or mitomycin).
High risk: Any high-grade tumor (Ta HG, T1, CIS). Treated with TURBT + BCG induction and maintenance. Close surveillance. Early cystectomy discussion for very-high-risk features.
Very high risk: T1 HG with CIS, lymphovascular invasion, variant histology (micropapillary, plasmacytoid), or multiple/large T1 HG tumors. Immediate radical cystectomy should be strongly considered alongside BCG.

A single dose of intravesical chemotherapy (gemcitabine 2 g or mitomycin C 40 mg) instilled into the bladder within 24 hours of TURBT reduces the risk of recurrence by approximately 35% for low- and intermediate-risk tumors. This is a standard of care that is sometimes missed — ask your urologist whether you received or should receive a post-TURBT instillation.

BCG Therapy — The Gold Standard for High-Risk NMIBC

Bacillus Calmette-Guérin (BCG) is a live attenuated strain of Mycobacterium bovis, originally developed as a tuberculosis vaccine. When instilled into the bladder, BCG triggers a powerful local immune response that attacks cancer cells. BCG remains the most effective intravesical treatment for reducing both recurrence and progression in high-risk NMIBC.

Induction: 6 weekly instillations, starting 2–4 weeks after TURBT. A catheter is inserted, BCG is instilled, the patient holds the solution in the bladder for approximately 2 hours, then voids.
Maintenance (SWOG protocol): After induction, 3 weekly instillations at 3 months, 6 months, and then every 6 months for up to 3 years. Maintenance BCG has been shown to significantly reduce recurrence compared to induction alone.
Side effects: Urgency, frequency, burning with urination, flu-like symptoms, low-grade fever. These are actually signs that the immune system is responding. Serious complications (BCG sepsis) are rare but require immediate treatment.
Response assessment: Cystoscopy and cytology at 3 months after starting BCG. For CIS, a complete response (negative cytology and cystoscopy) is the goal.

There has been a global BCG shortage affecting bladder cancer patients since 2019, caused by manufacturing difficulties and limited producers worldwide. Only two manufacturers (Merck and Sanofi) produce BCG for bladder cancer globally. Key points:

Induction BCG should be prioritized over maintenance when supply is limited
Reduced-dose BCG (one-third to one-half dose) maintains efficacy for some patients
Alternative intravesical agents (gemcitabine + docetaxel combination, mitomycin C, valrubicin) may be used when BCG is unavailable
The shortage is expected to persist through 2026–2027
Ask your urologist about BCG availability and alternative treatment plans

Ask your urologist: “Is BCG available at your center? If supply is limited, what is your plan — will I receive full-dose induction, reduced-dose, or an alternative intravesical regimen?”

What is my risk category (low, intermediate, high, very high)?
Will I receive BCG? Full dose or reduced dose? With maintenance?
Did I receive a single post-TURBT intravesical chemotherapy dose?
How often will I have surveillance cystoscopy?
What happens if BCG does not work or my cancer comes back?
At what point should we discuss radical cystectomy?
Am I eligible for any clinical trials?
Should I quit smoking, and what resources are available to help?

BCG-Unresponsive Disease — When BCG Stops Working

BCG-unresponsive bladder cancer is defined as high-grade NMIBC that persists or recurs after adequate BCG therapy (at least 5 of 6 induction doses plus at least 2 of 3 maintenance doses, or 2 induction courses). This is a critical juncture: the cancer has demonstrated resistance to the most effective intravesical treatment.

Radical cystectomy (surgical removal of the bladder) remains the gold standard treatment for BCG-unresponsive NMIBC. It offers the highest cure rate. However, it is a major operation with significant impact on quality of life (requiring urinary diversion), and not all patients are willing or medically fit for surgery.

FDA-APPROVED Nadofaragene firadenovec is an adenovirus-based gene therapy that delivers the interferon alfa-2b gene directly into bladder cells. Instilled via catheter (like BCG), the treated cells produce high local concentrations of interferon that stimulate anti-tumor immune activity. FDA-approved December 2022 for BCG-unresponsive NMIBC with CIS (with or without papillary disease). In the pivotal trial, approximately 53% of CIS patients achieved a complete response at 3 months, and about 24% maintained response at 12 months. Given every 3 months.

FDA-APPROVED Pembrolizumab (a PD-1 checkpoint inhibitor given intravenously) is FDA-approved for BCG-unresponsive, high-risk NMIBC with CIS who are ineligible for or have elected not to undergo cystectomy. The KEYNOTE-057 trial (NCT02625961) showed a complete response rate of approximately 41% at 3 months, with a median duration of response of about 16 months. This is a systemic (IV) therapy rather than intravesical.

Gemcitabine + docetaxel (intravesical): A combination of two chemotherapy drugs instilled into the bladder. Growing evidence from retrospective studies shows response rates of 50–65% in BCG-unresponsive disease. Not FDA-approved for this indication but widely used in clinical practice.
Valrubicin (Valstar): FDA-approved for BCG-refractory CIS. Response rates are modest (~18% CR). Rarely used as a first choice but may be an option when other treatments are unavailable.
Gemcitabine alone (intravesical): Used when BCG is unavailable. Less effective than BCG but better tolerated.

Critical decision point: If your NMIBC has not responded to BCG, discuss all options thoroughly with your urologist: radical cystectomy (most definitive cure), nadofaragene firadenovec, pembrolizumab, gemcitabine + docetaxel, or clinical trials. The risk of progression to muscle-invasive disease is real and increases with time. Do not delay this discussion.

Muscle-Invasive Bladder Cancer (MIBC)

Muscle-invasive bladder cancer (stage T2 or higher) has grown into the detrusor muscle of the bladder wall. This is a more serious diagnosis that typically requires aggressive treatment. The two main approaches are: (1) neoadjuvant chemotherapy followed by radical cystectomy, or (2) trimodality therapy (bladder-sparing approach).

Neoadjuvant (pre-surgery) cisplatin-based chemotherapy improves overall survival by approximately 5–8% compared to surgery alone. The standard regimens are:

Dose-dense MVAC (ddMVAC): Methotrexate, vinblastine, doxorubicin, cisplatin given every 2 weeks for 3–4 cycles with growth factor support. The preferred regimen in many US centers.
Gemcitabine + cisplatin (GC): Gemcitabine and cisplatin every 3 weeks for 4 cycles. Better tolerated than ddMVAC with similar efficacy in many studies.

Key point: Only cisplatin-based chemotherapy has proven neoadjuvant benefit. If you cannot receive cisplatin (due to kidney function, hearing loss, heart failure, or poor performance status), neoadjuvant chemotherapy is generally not recommended — proceed directly to surgery or consider a clinical trial.

Radical cystectomy involves removal of the entire bladder plus surrounding tissues:

In men: Bladder, prostate, seminal vesicles, and pelvic lymph nodes
In women: Bladder, uterus, ovaries, anterior vaginal wall, and pelvic lymph nodes

Urinary diversion options after cystectomy:

Ileal conduit (urostomy): A segment of intestine connects the ureters to an external stoma (opening on the abdomen). Urine drains continuously into a bag. Most common and simplest diversion.
Continent cutaneous diversion (Indiana pouch): An internal reservoir made from intestine with a valve mechanism. The patient catheterizes through a small stoma to empty the pouch.
Orthotopic neobladder: A new bladder is fashioned from intestine and connected to the urethra, allowing the patient to void somewhat normally. Requires significant patient motivation and education. Not everyone is a candidate.

Surgical volume matters. Radical cystectomy outcomes are significantly better at high-volume centers (those performing more than 20–25 cystectomies per year). Complication rates and mortality are measurably lower at experienced centers. This is one of the strongest volume-outcome relationships in oncologic surgery.

Nivolumab (Opdivo) adjuvant: The CheckMate-274 trial (NCT02632409) showed nivolumab after radical cystectomy in high-risk patients (pT3, pT4, or node-positive, especially if cisplatin-ineligible and did not receive neoadjuvant chemo) approximately doubled disease-free survival compared to placebo. FDA-approved.
Adjuvant cisplatin-based chemotherapy: For patients who did not receive neoadjuvant chemotherapy and have high-risk pathologic features (pT3/T4 or node-positive). Evidence is weaker than for neoadjuvant chemotherapy.

Am I a candidate for cisplatin-based neoadjuvant chemotherapy?
How many radical cystectomies does your center perform per year?
What urinary diversion options am I a candidate for?
Am I a candidate for bladder preservation (trimodality therapy)?
Should I see both a urologic oncologist and a medical oncologist?
What is the plan if my pathology after surgery shows high-risk features?
Am I eligible for adjuvant nivolumab?
Are there clinical trials available for my situation?

Bladder Preservation — Trimodality Therapy (TMT)

Trimodality therapy (TMT) is an alternative to radical cystectomy that aims to cure muscle-invasive bladder cancer while preserving the native bladder. It combines maximal TURBT, concurrent chemotherapy, and radiation therapy.

Maximal TURBT: As much visible tumor as possible is resected.
Concurrent chemoradiation: Radiation therapy to the bladder (typically 60–64 Gy over 6–7 weeks) given concurrently with radiosensitizing chemotherapy (most commonly gemcitabine, cisplatin, or 5-FU + mitomycin C).
Response assessment: Cystoscopy and biopsy after initial treatment. If complete response, continue to completion. If incomplete response, proceed to salvage cystectomy.

Outcomes: Long-term studies from Massachusetts General Hospital and the BC2001 trial show 5-year overall survival rates of approximately 50–60% with TMT, comparable to radical cystectomy in well-selected patients. About 70–80% of long-term survivors retain their native bladder.

Best candidates for TMT: Unifocal T2 disease, complete TURBT, no CIS, no hydronephrosis, adequate bladder function, committed to close surveillance.

TMT is preferred more in the UK and Europe than in the US, where radical cystectomy remains the dominant approach. Both are considered acceptable standards by NCCN.

Metastatic Bladder Cancer

Metastatic bladder cancer means the cancer has spread beyond the pelvis to distant sites — most commonly the lungs, bones, liver, or distant lymph nodes. The treatment landscape for metastatic bladder cancer has changed dramatically, with multiple new treatment options now available.

FDA-APPROVED The EV-302/KEYNOTE-A39 trial (NCT04223856) is the landmark trial that changed first-line treatment for advanced urothelial carcinoma. Key results:

Median OS: 31.5 months vs. 16.1 months with platinum-based chemotherapy
Median PFS: 12.5 months vs. 6.3 months
Objective response rate: 67.7% vs. 44.4%
Complete response rate: 29.1% vs. 12.5%
Benefit seen regardless of cisplatin eligibility and PD-L1 status

This combination is now the preferred first-line treatment for locally advanced or metastatic urothelial carcinoma per NCCN guidelines.

Before EV-302, platinum-based chemotherapy was the first-line standard. It remains an option when enfortumab vedotin is not available or contraindicated:

Gemcitabine + cisplatin (GC): Standard for cisplatin-eligible patients. Requires adequate kidney function (GFR ≥60 mL/min), no significant hearing loss, no severe neuropathy, and ECOG performance status 0–1.
Gemcitabine + carboplatin: For cisplatin-ineligible patients. Less effective but better tolerated.
Dose-dense MVAC (ddMVAC): More intensive but higher response rates. Typically 4–6 cycles.

If chemotherapy is used first line: patients who do not progress should receive avelumab maintenance therapy (JAVELIN Bladder 100).

FDA-APPROVED JAVELIN Bladder 100 (NCT02603432) showed that switching to avelumab maintenance after first-line platinum-based chemotherapy (in patients with CR, PR, or stable disease) improved median OS from 14.3 months to 21.4 months. This applies when chemotherapy (not EV + pembrolizumab) is used first line.

Am I eligible for enfortumab vedotin + pembrolizumab?
Am I cisplatin-eligible? What is my kidney function?
Has my tumor been tested for FGFR alterations?
What is my PD-L1 status, and does it affect my treatment options?
If I receive chemotherapy, will I switch to avelumab maintenance?
What side effects should I expect and how will they be managed?
Are there clinical trials available for my specific situation?
What is the goal of treatment — cure, long-term control, or symptom relief?

Targeted & Immunotherapy Options

Beyond the first-line setting, several targeted therapies and immunotherapies are available for bladder cancer, selected based on molecular testing, prior treatments, and individual patient factors.

FDA-APPROVED Erdafitinib targets FGFR3 and FGFR2 alterations (mutations or fusions) found in approximately 15–20% of advanced urothelial carcinomas. The THOR trial (NCT03390504) showed erdafitinib improved overall survival compared to chemotherapy in patients with FGFR-altered tumors who had progressed on prior therapy (12.1 months vs. 7.8 months). Key side effects include hyperphosphatemia, central serous retinopathy (requires ophthalmologic monitoring), and nail changes.

FDA-APPROVED Enfortumab vedotin (EV) is an antibody-drug conjugate that targets Nectin-4, a protein expressed on the surface of most urothelial cancer cells. It delivers a potent chemotherapy payload directly to cancer cells. The EV-301 trial showed EV monotherapy improved OS compared to chemotherapy in patients who had progressed after platinum-based chemotherapy and a checkpoint inhibitor. EV is also approved in combination with pembrolizumab as first-line therapy (EV-302). Key side effects include skin rash, peripheral neuropathy, and hyperglycemia — diabetic ketoacidosis has been reported and blood glucose should be monitored.

FDA-APPROVED Sacituzumab govitecan is an antibody-drug conjugate targeting Trop-2, approved for locally advanced or metastatic urothelial carcinoma that has progressed after platinum-based chemotherapy and a checkpoint inhibitor. The TROPiCS-04 trial showed a response rate of approximately 27% in this heavily pretreated population.

Several PD-1/PD-L1 checkpoint inhibitors are approved or used in bladder cancer:

Pembrolizumab (Keytruda): Approved for BCG-unresponsive CIS, and in combination with EV for first-line metastatic disease, and as monotherapy for platinum-ineligible patients with high PD-L1
Nivolumab (Opdivo): Approved as adjuvant therapy after radical cystectomy (CheckMate-274)
Avelumab (Bavencio): Approved as switch maintenance after first-line platinum chemotherapy (JAVELIN Bladder 100)
Atezolizumab (Tecentriq): Its earlier second-line metastatic bladder cancer indication was voluntarily withdrawn from the US market in 2024 after a confirmatory trial did not meet its overall survival endpoint. In May 2026 the FDA approved atezolizumab in a new, biomarker-defined setting — adjuvant (after-surgery) treatment of muscle-invasive bladder cancer (MIBC) after cystectomy for patients who have circulating tumor DNA molecular residual disease (ctDNA MRD) detected by an FDA-authorized test. This is the first ctDNA-guided immunotherapy approval in bladder cancer, based on the phase 3 IMvigor011 trial (NCT04660344).

Supportive Care

Bladder cancer treatment can cause significant side effects that require proactive management. Good supportive care improves both outcomes and quality of life.

Irritative voiding symptoms: Urgency, frequency, and burning are expected after BCG. Usually subside within 48 hours. Phenazopyridine (AZO) and anticholinergic medications may help.
Flu-like symptoms: Low-grade fever, fatigue, and body aches for 24–48 hours. Acetaminophen is usually sufficient.
BCG sepsis: Rare but serious. High fever (>101.3°F / 38.5°C lasting >24 hours), persistent illness, or signs of systemic infection require urgent evaluation and anti-tuberculosis antibiotics (isoniazid, rifampin, ethambutol).

Ostomy care: An enterostomal therapy (ET) nurse is essential for learning stoma care, appliance management, and skin protection. Most patients become independent within weeks.
Sexual function: Radical cystectomy affects sexual function in both men and women. Nerve-sparing techniques are available for select patients. Erectile dysfunction resources, vaginal rehabilitation, and pelvic floor therapy should be discussed proactively.
Nutritional considerations: Intestinal segments used for urinary diversion can cause metabolic changes (metabolic acidosis, vitamin B12 deficiency). Periodic monitoring of electrolytes and B12 is recommended.
Psychosocial support: Body image changes, adjustment to urinary diversion, and cancer-related anxiety are common. Support groups, psychology services, and peer mentors are valuable resources.

Immune-related adverse events (irAEs): Checkpoint inhibitors can cause the immune system to attack normal tissues. Common irAEs include skin rash, thyroid dysfunction, colitis (diarrhea), hepatitis, and pneumonitis.
Enfortumab vedotin specific: Skin rash (may be severe), peripheral neuropathy (tingling/numbness in hands/feet), hyperglycemia (monitor blood sugar, risk of diabetic ketoacidosis), and fatigue.
Erdafitinib specific: Hyperphosphatemia (managed with phosphate binders and dietary restriction), central serous retinopathy (regular eye exams), and nail changes.
Report symptoms promptly. Many irAEs are treatable with steroids if caught early but can become serious if ignored.

class="content-section" data-stage="advanced">

Clinical Trials — Finding and Enrolling

Clinical trials are important at every stage of bladder cancer, from BCG-unresponsive NMIBC to metastatic disease. Trials offer access to promising therapies not yet commercially available.

Trial	Agent(s)	Population	NCT Number
EV-302/KEYNOTE-A39	Enfortumab vedotin + pembrolizumab	1L advanced urothelial carcinoma	NCT04223856
THOR	Erdafitinib vs. chemo	FGFR-altered, previously treated	NCT03390504
CheckMate-274	Nivolumab adjuvant	High-risk MIBC post-cystectomy	NCT02632409
JAVELIN Bladder 100	Avelumab maintenance	After 1L platinum chemo	NCT02603432
SunRISe-1 / SunRISe-2	TAR-200 / Inlexzo (intravesical gemcitabine)	BCG-unresponsive NMIBC / MIBC	NCT04640623 / NCT05714202
KEYNOTE-057	Pembrolizumab	BCG-unresponsive NMIBC CIS	NCT02625961
VOLGA	Durvalumab + tremelimumab + EV	Cisplatin-ineligible MIBC (neoadj.)	NCT04960709
NIAGARA	Durvalumab + GC (neoadjuvant + adjuvant)	Cisplatin-eligible MIBC	NCT03732677
POTOMAC	Durvalumab + BCG (FDA-approved)	High-risk BCG-naïve NMIBC	NCT03528694

ClinicalTrials.gov (clinicaltrials.gov): Search for “urothelial carcinoma” or “bladder cancer” and filter by status, location, and stage.
Bladder Cancer Advocacy Network (BCAN): bcan.org — Clinical trial finder and patient education
National Cancer Institute (NCI): 1-800-4-CANCER (1-800-422-6237)
Your academic center: Many centers run trials not widely advertised. Ask your urologic oncologist and medical oncologist about open trials.

International Access & Regulatory Landscape

Bladder cancer drug approvals and treatment approaches vary by country and region.

Drug	US FDA	EMA (Europe)	Notes
Enfortumab vedotin + pembrolizumab	Approved 2023 (1L)	Approved 2024	New global first-line standard
Erdafitinib	Approved 2024 (full)	Approved 2024	Requires FGFR companion diagnostic
Nadofaragene firadenovec	Approved 2022	Not yet approved	US only; supply constraints
Avelumab (maintenance)	Approved 2020	Approved 2021	Broadly available
Nivolumab (adjuvant)	Approved 2021	Approved 2021	Broadly available

BCG shortage is global. The shortage affects countries worldwide. Alternative intravesical regimens vary by national guidelines (NICE, EAU, NCCN). Some countries have access to different BCG strains (TICE, Connaught, OncoTICE, Tokyo-172).

Trimodality therapy (TMT) is more widely adopted in the UK than in the United States, where radical cystectomy remains dominant. EAU and NICE guidelines support TMT as an equivalent option for selected patients.

Cisplatin eligibility criteria differ. US guidelines typically use GFR ≥60 mL/min as the threshold for cisplatin eligibility; European guidelines sometimes use GFR ≥50 mL/min with split-dose cisplatin protocols.

NCCN (US): Comprehensive treatment algorithms updated multiple times per year
AUA/SUO (US): NMIBC-specific guidelines (2024 update)
EAU (European Association of Urology): Widely adopted NMIBC and MIBC guidelines
ESMO: European clinical practice guidelines for urothelial carcinoma
NICE (UK): Technology appraisals determining NHS access
Health Canada / CADTH: Canadian drug access pathway
PMDA (Japan): Japanese regulatory authority

Failed & De-Adopted Therapies

Understanding what has been tried and did not work helps patients and families evaluate new claims and avoid treatments with proven lack of benefit.

WITHDRAWN Atezolizumab received accelerated FDA approval in 2016 for second-line metastatic urothelial carcinoma based on single-arm data. However, the confirmatory IMvigor211 trial failed to show overall survival benefit over chemotherapy. Atezolizumab's metastatic urothelial indications were voluntarily withdrawn from the US market in 2024. The first-line indication (IMvigor130, cisplatin-ineligible with high PD-L1) was also withdrawn. Atezolizumab remains available for other cancer types.

Update: Atezolizumab is not gone from bladder cancer entirely. The FDA has since approved it (and the Tecentriq Hybreza subcutaneous formulation) as adjuvant treatment of muscle-invasive bladder cancer (MIBC) after cystectomy in patients who have circulating tumor DNA molecular residual disease (ctDNA MRD) detected by an FDA-authorized test (IMvigor011). This is a distinct, biomarker-selected setting from the withdrawn metastatic indications above. Ask your oncologist whether ctDNA MRD testing applies to your situation.

DE-ADOPTED Intravesical interferon-alfa as a single agent for NMIBC was studied extensively but found to have inferior efficacy compared to BCG. It is no longer recommended as monotherapy. However, the concept of local interferon production is the basis of nadofaragene firadenovec (Adstiladrin), which delivers the interferon gene directly into bladder cells for sustained local production.

NOT EFFECTIVE Carboplatin-based combinations have not been shown to provide neoadjuvant survival benefit in muscle-invasive bladder cancer. Only cisplatin-based neoadjuvant chemotherapy has proven benefit. This distinction is critical: if you cannot receive cisplatin, neoadjuvant chemotherapy is generally not recommended. Consider proceeding directly to surgery or enrolling in a clinical trial testing perioperative immunotherapy.

FAILED The DANUBE trial (NCT02516241) tested durvalumab (with or without tremelimumab) versus chemotherapy as first-line treatment for metastatic urothelial carcinoma. Neither durvalumab monotherapy nor the durvalumab + tremelimumab combination improved overall survival compared to platinum-based chemotherapy. This confirmed that checkpoint inhibitor monotherapy is not sufficient to replace chemotherapy in the first-line setting for unselected patients.

Why this matters: If someone suggests one of these therapies, you now know its history. Always ask your oncologist: “Has this been tested in a randomized phase 3 trial for bladder cancer, and what were the results?”

class="content-section" data-stage="resources">

Specialty Centers

Bladder cancer outcomes — particularly for radical cystectomy — are significantly better at high-volume centers. Surgical volume is one of the strongest predictors of outcomes in bladder cancer surgery. A second opinion from a high-volume center is strongly recommended for muscle-invasive or BCG-unresponsive disease.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

Huntsman Cancer Institute (HCI) — University of Utah

NCI-designated Comprehensive Cancer Center with dedicated genitourinary oncology program

Location: 2000 Circle of Hope Dr, Salt Lake City, UT 84112
Phone: 801-585-0303
Programs: Genitourinary Cancers Program with high-volume cystectomy, robotic surgery, bladder preservation protocols, clinical trials for NMIBC and metastatic disease. Multidisciplinary tumor board for bladder cancer.

Why it matters. HCI is the only NCI-designated Comprehensive Cancer Center in the Mountain West region. Its GU oncology program offers the full range of bladder cancer treatments including complex cystectomy, neobladder construction, trimodality therapy, and clinical trial access.

University of Utah Health — Department of Urology

Location: Salt Lake City, UT
Phone: 801-581-2121
Services: Urologic oncology, TURBT, cystectomy, urinary diversion, bladder cancer surveillance.

Intermountain Health

Location: Multiple Utah locations
Phone: 801-442-2000
Services: Community-based urology and medical oncology. BCG treatment. Referral pathways to HCI for complex cases.

Mayo Clinic Arizona

Location: 5777 E Mayo Blvd, Phoenix, AZ 85054
Phone: 480-301-8000
Programs: GU oncology program, robotic cystectomy, clinical trials.

University of Colorado Cancer Center

Location: Anschutz Medical Campus, Aurora, CO 80045
Phone: 720-848-0000
Programs: NCI Comprehensive Cancer Center. GU oncology program with active bladder cancer trials.

How to choose. Huntsman Cancer Institute = NCI Comprehensive Cancer Center with full GU oncology program, clinical trials, and multidisciplinary tumor board. Intermountain Health = community-based care, often in-network, broad geographic coverage, with referral pathways to HCI for complex cases.

Information verified May 2026. Availability changes — confirm with each institution directly.

Memorial Sloan Kettering Cancer Center

Location: New York, NY · Phone: 212-639-2000
One of the world’s highest-volume bladder cancer surgery programs. Pioneer in neobladder reconstruction, robotic cystectomy, and bladder cancer clinical trials.

MD Anderson Cancer Center

Location: Houston, TX · Phone: 877-632-6789
Large GU oncology program with extensive clinical trial portfolio for bladder cancer at all stages.

Johns Hopkins Sidney Kimmel Cancer Center

Location: Baltimore, MD · Phone: 410-955-5000
Greenberg Bladder Cancer Institute. High-volume cystectomy program. Active in immunotherapy and targeted therapy trials.

University of Michigan Rogel Cancer Center

Location: Ann Arbor, MI · Phone: 734-936-4000
High-volume cystectomy center. Pioneer in enhanced recovery after cystectomy (ERAS) protocols. Active bladder cancer research.

Dana-Farber Cancer Institute / Brigham and Women’s

Location: Boston, MA · Phone: 617-632-3000
GU oncology program with active trials in immunotherapy, targeted therapy, and bladder preservation.

Cleveland Clinic — Glickman Urological Institute

Location: Cleveland, OH · Phone: 866-588-2264
High-volume urologic surgery program with robotic cystectomy and neobladder expertise.

VA Salt Lake City Health Care System (George E. Wahlen VAMC)

Phone: 801-582-1565
Urology and hematology/oncology services. Partnership with Huntsman Cancer Institute for complex surgical cases and clinical trials. Veterans with muscle-invasive or BCG-unresponsive disease should request referral to HCI through VA Community Care.

VA Cancer Care Network

The VA system provides bladder cancer care through its medical centers. For complex cases requiring radical cystectomy or clinical trial access, the VA partners with academic centers through community care arrangements.

Request referral to a high-volume academic center for second opinion
Ask about community care authorization for cystectomy at a high-volume center
Clinical trial access through VA-academic partnerships

VA Cancer Care: cancer.va.gov
VA Community Care: 1-877-881-7618

Princess Margaret Cancer Centre (UHN), Toronto

Location: 610 University Avenue, Toronto, ON M5G 2M9
Phone: 416-946-4501
Major GU oncology program with high-volume cystectomy, bladder preservation, and clinical trials.

BC Cancer — Vancouver Centre

Location: Vancouver, BC
Phone: 604-877-6000
Provincial cancer center with bladder cancer treatment and trials.

McGill University Health Centre, Montreal

Location: Montréal, QC
Phone: 514-934-1934
GU oncology program with bladder cancer surgery and systemic therapy.

Bladder Cancer Canada: bladdercancercanada.org
Canadian Cancer Society helpline: 1-888-939-3333

International Centers of Excellence for Bladder Cancer

University College London Hospital (UCLH), UK: Major TMT center; leader in bladder preservation approaches
Institut Gustave Roussy, Paris, France: European leader in GU oncology trials
Leiden University Medical Centre, Netherlands: EAU guideline development center
Universitätsklinikum Tübingen, Germany: High-volume cystectomy center in Europe
National Cancer Center Hospital, Tokyo, Japan: Active in bladder cancer drug development
Peter MacCallum Cancer Centre, Melbourne, Australia: Australian GU oncology trials center

Caregiver Guidance

Caring for someone with bladder cancer involves navigating a wide range of challenges, from frequent surveillance cystoscopies to major surgery and systemic therapy. The caregiving burden varies considerably depending on the stage and treatment approach.

Surveillance is ongoing. Bladder cancer has one of the highest recurrence rates of any cancer. Patients with NMIBC require regular cystoscopies (every 3–6 months initially, then annually) for years, sometimes lifelong. Each cystoscopy can cause anxiety (“scanxiety”).
BCG side effects need management. Help track symptoms after BCG instillations. Ensure over-the-counter symptom relief is available. Know the signs of BCG sepsis (high sustained fever).
Emotional toll of chronic surveillance. Living with a cancer that may recur repeatedly is psychologically exhausting. Support groups and counseling can help both patients and caregivers.

Expect a significant recovery period. Radical cystectomy typically requires 5–7 days of hospitalization and 6–12 weeks of recovery at home. Enhanced recovery protocols have shortened this at many centers.
Learn stoma care together. If an ileal conduit (urostomy) is created, both patient and caregiver should learn stoma care from the enterostomal therapy nurse before discharge.
Watch for complications. Dehydration, urinary tract infections, bowel complications (ileus), and electrolyte imbalances are common in the first weeks after surgery.
Adjust to the new normal. Body image changes, sexual function changes, and the practical aspects of managing urinary diversion require patience, adaptation, and open communication.

Bladder Cancer Advocacy Network (BCAN): bcan.org — Patient education, support groups, survivorship resources, clinical trial finder
American Cancer Society: 1-800-227-2345 — General cancer support and resources
National Cancer Institute: 1-800-422-6237 — Cancer information and clinical trial matching
United Ostomy Associations of America (UOAA): ostomy.org — For patients with urinary diversions
Cancer Support Community: 1-888-793-9355 — Free counseling, support groups, education

Fertility Preservation & Pregnancy with Bladder Cancer

Bladder cancer most often affects older adults, but when it occurs in younger people, fertility and pregnancy considerations become important. Treatments for bladder cancer — including surgery, chemotherapy, and radiation — can affect fertility.

How treatment can affect fertility

Radical cystectomy (bladder removal): In women, this surgery often removes the uterus, ovaries, and part of the vagina, ending the ability to carry a pregnancy naturally. In men, it typically causes changes that may prevent natural conception (retrograde ejaculation or loss of ejaculation). Discuss fertility-sparing surgical options if this is a concern before surgery.
Chemotherapy (platinum agents, enfortumab vedotin): can damage eggs and sperm. Cisplatin and other chemotherapy drugs used for bladder cancer are harmful to a developing baby and are teratogenic — pregnancy must be avoided during treatment.
Immunotherapy (checkpoint inhibitors like pembrolizumab, atezolizumab, nivolumab): contraindicated in pregnancy due to risk of immune attack on placental tissue and the fetus.
FGFR inhibitor (erdafitinib): teratogenic — effective contraception required during treatment and for a period after stopping.
Pelvic radiation: damages ovarian function and the uterus in women, and damages sperm production in men.

Fertility preservation: act before treatment starts

Women: Consider egg or embryo freezing before chemotherapy, radiation, or cystectomy. Ask your oncologist about ovarian transposition (surgically moving the ovaries out of the radiation field) if pelvic radiation is planned.
Men: Sperm banking before any surgery, chemotherapy, or radiation is strongly recommended if you wish to have children in the future.
Fertility preservation must happen before treatment begins — ask for a referral to a reproductive medicine specialist as soon as possible after diagnosis.

Pregnancy after bladder cancer treatment

Most oncologists recommend waiting at least 2 years after completing treatment before trying to conceive, to reduce the chance that the cancer has returned before a pregnancy begins.
If your uterus was preserved (possible with bladder-sparing treatment approaches), pregnancy may still be possible, but may carry higher-risk features (uterine scarring from radiation, altered anatomy).
If you had a radical cystectomy but preserved your uterus (rare but sometimes possible), discuss the possibility of surrogacy or adoption with your medical and support team.

Bladder cancer diagnosed during pregnancy

Bladder cancer is very rarely diagnosed during pregnancy. When it happens, management is individualized by a team that includes a urologic oncologist and a maternal-fetal medicine specialist, weighing your cancer needs against the stage of pregnancy. Most treatments can be timed and adapted to minimize fetal risk.

Glossary

BCG: Bacillus Calmette-Guérin. A live attenuated tuberculosis vaccine instilled into the bladder to treat non-muscle-invasive bladder cancer.
BCG-unresponsive: High-grade NMIBC that persists or recurs after adequate BCG therapy. A critical decision point for treatment.
Carcinoma in situ (CIS/Tis): Flat, high-grade cancer confined to the bladder lining. Aggressive biology despite flat appearance. Treated with BCG.
Cisplatin-eligible: Meeting criteria to safely receive cisplatin chemotherapy: adequate kidney function (GFR ≥60), no hearing loss, acceptable performance status.
Cystectomy: Surgical removal of the bladder. “Radical” cystectomy removes bladder plus surrounding organs and lymph nodes.
Cystoscopy: A procedure using a thin camera inserted through the urethra to examine the inside of the bladder.
Enfortumab vedotin (EV/Padcev): An antibody-drug conjugate targeting Nectin-4. Used alone or with pembrolizumab for advanced urothelial carcinoma.
Erdafitinib (Balversa): A targeted therapy for FGFR-altered urothelial carcinoma.
FGFR: Fibroblast growth factor receptor. FGFR3/FGFR2 alterations in ~15–20% of advanced bladder cancers are targetable by erdafitinib.
Hematuria: Blood in the urine. The most common presenting symptom of bladder cancer.
Ileal conduit: A type of urinary diversion using a segment of intestine to connect ureters to an external stoma.
Intravesical therapy: Treatment instilled directly into the bladder through a catheter (e.g., BCG, gemcitabine, mitomycin C).
MIBC: Muscle-invasive bladder cancer. Cancer that has grown into the muscularis propria (deep muscle) of the bladder wall.
Nadofaragene firadenovec (Adstiladrin): First gene therapy for bladder cancer. An adenovirus delivering the interferon gene for BCG-unresponsive NMIBC.
Neoadjuvant: Treatment given before the primary therapy (usually surgery). Neoadjuvant cisplatin-based chemotherapy improves survival in MIBC.
Neobladder: A new bladder fashioned from intestine and connected to the urethra, allowing near-normal voiding after cystectomy.
NMIBC: Non-muscle-invasive bladder cancer. Includes stages Ta, T1, and CIS (Tis). Treated with TURBT and intravesical therapy.
PD-1/PD-L1: Immune checkpoint proteins. Pembrolizumab blocks PD-1; avelumab blocks PD-L1. These enable the immune system to attack cancer.
TMT: Trimodality therapy. Bladder-sparing approach combining maximal TURBT, concurrent chemotherapy, and radiation.
TURBT: Transurethral resection of bladder tumor. The primary diagnostic and initial therapeutic procedure for bladder cancer.
Urothelial carcinoma: Cancer arising from the urothelium (lining of the urinary tract). The most common type of bladder cancer (~90%).

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and the work of physicians treating bladder cancer across multiple countries. Key sources are listed below.

Primary Resources

PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
NCCN Guidelines — Bladder Cancer (nccn.org) — Treatment algorithms followed by oncologists
Bladder Cancer Advocacy Network (BCAN) (bcan.org) — Patient education, support, clinical trial finder
National Cancer Institute (NCI) (cancer.gov) — Comprehensive bladder cancer information
AUA/SUO Guidelines (auanet.org) — NMIBC management guidelines

Key Guideline and Trial References

EV-302/KEYNOTE-A39: Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875–888. (NCT04223856)
JAVELIN Bladder 100: Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230. (NCT02603432)
CheckMate-274: Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102–2114. (NCT02632409)
THOR: Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961–1971. (NCT03390504)
POTOMAC: durvalumab + BCG in BCG-naive high-risk NMIBC (NCT03528694)
IMvigor011: adjuvant atezolizumab in ctDNA-positive MIBC (NCT04660344)
AUA/SUO NMIBC Guidelines 2024: Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline amendment 2024. J Urol. 2024.
EAU MIBC Guidelines 2024: Witjes JA, Bruins HM, Cathélijn R, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. European Association of Urology, 2024.

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.

What This Guide Does Not Know

An honest guide names its own limits:

This guide cannot diagnose, stage, or treat anyone. It does not know your tumor grade, depth of invasion, molecular profile, kidney function, or personal preferences. Only your medical team can build an actual plan.
Bladder cancer treatment is evolving rapidly. New approvals, trial results, and guideline updates occur frequently. Every time-sensitive fact should be re-verified with your team, on FDA.gov, and on ClinicalTrials.gov.
Drug approvals and availability vary by country. This guide focuses primarily on FDA-approved therapies. Access differs in Europe, Asia, Canada, and other regions.
Individual outcomes cannot be predicted. Statistics describe populations, not individuals. Two patients with the same stage can have very different courses.
Surgical volume matters enormously. Cystectomy outcomes vary significantly between low-volume and high-volume centers. This guide cannot assess your surgeon’s experience or your institution’s outcomes.

A final word. Bladder cancer treatment has changed more in the past five years than in the preceding decades. Enfortumab vedotin + pembrolizumab has transformed outcomes for advanced disease. Nadofaragene firadenovec and pembrolizumab have given new options when BCG fails. Erdafitinib brings precision medicine to bladder cancer. And the pipeline is active, with TAR-200 and perioperative immunotherapy approaches in late-stage trials. Get to a center with experience. Ask about trials. Bring this guide to your appointments. The landscape is improving, and you deserve access to the best available care.